Eli Lilly and Co said on Thursday it plans to start a rolling submission to the U.S. Food and Drug Administration (FDA) this year to get an approval for its obesity drug tirzepatide.
The data it will submit will include that from two late-stage trials, one of which is expected in April.
The FDA has also granted "Fast Track" designation for the drug to treat obesity or overweight with weight-related comorbidities in adults, under which the regulator expedites the review of medicines to treat serious conditions and fill an unmet medical need.
https://finance.yahoo.com/news/1-eli-lilly-start-rolling-114649301.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.